Investigation into Soleno Therapeutics, Inc.
In a notable development, legal investigations have been launched regarding Soleno Therapeutics, Inc. (NASDAQ: SLNO). The investigations are centered around potential violations of U.S. federal securities laws. It has been alleged that Soleno and certain top executives may have made misleading statements or failed to disclose crucial information to their investors.
Impact on Investors
For investors in Soleno Therapeutics, this hypothesis poses significant concerns. If you believe you have relevant information that may assist in the ongoing investigation or if you happen to be an investor who has suffered financial loss, it’s crucial to seek guidance. Legal counsel can often provide clarity and assistance in understanding your status and potential actions.
Recent Company Developments
Earlier in the year, specifically on March 26, 2025, Soleno announced the approval of VYKAT XR (diazoxide choline) extended-release tablets by the U.S. Food and Drug Administration. This drug is intended for treating hyperphagia in patients diagnosed with Prader-Willi syndrome, marking a promising milestone for the company.
Quarterly Earnings Call
However, during a quarterly earnings call on November 4, 2025, critical information came to light. It was disclosed that approximately 8% of patients discontinued VYKAT XR due to adverse effects by the third quarter. CEO Anish Bhatnagar further revealed that a short seller's report released in August impacted the launch trajectory of VYKAT XR, evident through decreased starting forms and increased discontinuations for non-serious adverse events. Following this news, Soleno's stock price witnessed a steep decline of more than 26%, exacerbating concerns among investors.
About Robbins Geller Rudman & Dowd LLP
Robbins Geller Rudman & Dowd LLP stands out as a leading law firm with a focus on representing investors in securities fraud cases and shareholder litigation. They have consistently ranked high in the ISS Securities Class Action Services rankings, claiming the top position for the recovery amounts achieved for investors in recent years. In 2024 alone, they recovered over $2.5 billion for investors involved in class actions related to securities, highlighting their commitment and effectiveness.
Legal Representation and Assistance
The firm, which operates with 200 lawyers spread across ten offices, has managed to secure some of the largest recoveries in securities class action history. This includes the remarkable $7.2 billion recovery achieved in the infamous Enron Corporation securities litigation. Investors seeking additional information or legal assistance are encouraged to reach out to Robbins Geller. Potential witnesses or individuals with valuable information are essential to the trajectory of the investigation.
Frequently Asked Questions
What is the investigation about?
The investigation concerns potential violations of U.S. federal securities laws related to misleading statements made by Soleno Therapeutics and its executives.
Who can be affected by this investigation?
Investors in Soleno Therapeutics who may have suffered losses are particularly affected, as well as anyone with relevant information about the company’s statements and actions.
What should I do if I have information?
If you possess information that could assist the investigation, consider contacting Robbins Geller or seeking legal counsel to understand the implications of your information.
What recent event affected Soleno's stock price?
The stock price of Soleno dropped by over 26% following the revelation of an increased discontinuation rate for VYKAT XR due to adverse effects.
How can Robbins Geller assist investors?
Robbins Geller can provide legal representation, advice, and resources to investors and individuals involved in or affected by the investigation.
